Clinical trial
Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent…
NCT00139841 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00139841 |
|---|---|
| Title | Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab |
| Official title | A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Bendamustine HCl |
| Enrollment | 103 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Oct 1, 2009 |
| First posted | Aug 31, 2005 |
| Last update posted | May 9, 2014 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: